Press Releases

06.24.2022

Pfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with Analysts

06.23.2022

Valneva and Pfizer Announce Closing of Equity Investment

06.23.2022

Pfizer Declares Third-Quarter 2022 Dividend

06.20.2022

Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15

06.17.2022

Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age

06.17.2022

Myovant Sciences and Pfizer Announce Publication in The Lancet of Phase 3 SPIRIT 1 and SPIRIT 2 Studies of Once-Daily Relugolix Combination Therapy in Women With Endometriosis-Associated Pain

06.14.2022

Pfizer Reports Additional Data on PAXLOVID™ Supporting Upcoming New Drug Application Submission to U.S. FDA

06.09.2022

Pfizer Completes Acquisition of ReViral

06.09.2022

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

06.08.2022

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

06.06.2022

Pfizer to Invest $120 Million to Produce COVID-19 Oral Treatment in the U.S.

06.04.2022

Pfizer Announces Overall Survival Results from Phase 3 PALOMA-2 Trial of IBRANCE® (palbociclib) for the First-Line Treatment of ER+, HER2- Metastatic Breast Cancer